Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226206 · ClinicalTrials.gov registry record · Phase 1
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
A Phase 1 study of Hemophilia A, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT07226206 is a Phase 1 study of Hemophilia A that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 5 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07226206, a Phase 1 study of Hemophilia A, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.
Conditions Studied
Interventions
- DRUG SPK-8011QQ
Study Locations (1)
California
- Kaiser Permanente - Vallejo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2031-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226206
The ClinicalTrials.gov registry entry for NCT07226206 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (95% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which SPK-8011QQ is the first listed.
NCT07226206 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07226206 about?
NCT07226206 is a clinical study titled "A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A". This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.
What is the current status of trial NCT07226206?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2026-03-31. Estimated completion is 2031-07-31.
What conditions does trial NCT07226206 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT07226206?
The interventions under investigation include: SPK-8011QQ (DRUG).
Who is sponsoring clinical trial NCT07226206?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226206 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
-
ASC618 Gene Therapy in Hemophilia A Patients
RECRUITING · Phase 1
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RECRUITING · Phase 1
-
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy for Haemophilia A.
ACTIVE NOT RECRUITING · Phase 1
-
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.